[CCR5, a new target of anti-HIV drugs]
- PMID: 14650176
[CCR5, a new target of anti-HIV drugs]
Abstract
CCR5, a membrane protein on cell surface, is a member of the G protein-coupled receptor superfamily and one of the major co-receptors for HIV-1 infection. The roles of CCR5 in HIV-1 infection have been elucidated since 1996. Because of the biological nature of CCR5, it has became a molecular target for the novel drugs against HIV-1. Antagonists for CCR5 could be grouped as following, chemokine derivatives, small molecule non-peptide compounds, monoclonal antibodies and peptides. The latest progress in this field is reviewed in this article.
Similar articles
-
HIV chemokine receptor inhibitors as novel anti-HIV drugs.Cytokine Growth Factor Rev. 2005 Dec;16(6):659-77. doi: 10.1016/j.cytogfr.2005.05.009. Epub 2005 Jul 6. Cytokine Growth Factor Rev. 2005. PMID: 16005254 Review.
-
Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor.Virology. 2009 Dec 20;395(2):268-79. doi: 10.1016/j.virol.2009.09.029. Epub 2009 Oct 20. Virology. 2009. PMID: 19846188
-
Identification of peptide ligands to the chemokine receptor CCR5 and their maturation by gene shuffling.Mol Immunol. 2006 Apr;43(10):1573-8. doi: 10.1016/j.molimm.2005.09.025. Epub 2005 Nov 8. Mol Immunol. 2006. PMID: 16280164
-
CCR5 antagonists: a new tool in fighting HIV.J HIV Ther. 2005 Dec;10(4):68-71. J HIV Ther. 2005. PMID: 16519245 Review.
-
Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.Antiviral Res. 2005 Nov;68(2):96-108. doi: 10.1016/j.antiviral.2005.07.006. Epub 2005 Aug 30. Antiviral Res. 2005. PMID: 16157392
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical